BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, vol. 53, No 8, p. 1627-1629. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.656104.

Basic information

• Original name: BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
• Authors: ŠIMARA, Pavel (203 Czech Republic, belonging to the institution), Martina PETERKOVÁ (203 Czech Republic, belonging to the institution), Stanislav STEJSKAL (203 Czech Republic, belonging to the institution), Michaela POTĚŠILOVÁ (203 Czech Republic, belonging to the institution), Irena KRONTORÁD KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Filip RÁZGA (703 Slovakia, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
• Edition: Leukemia & lymphoma, England, Informa Healthcare, 2012, 1042-8194.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.301
• RIV identification code: RIV/00216224:14330/12:00059688
• Organization unit: Faculty of Informatics
• Doi: http://dx.doi.org/10.3109/10428194.2012.656104
• UT WoS: 000306566000035
• Keywords in English: p-CrkL; chronic myeloid leukemia; imatinib
• Tags: cbia-web

Abstract

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Links

• GBP302/12/G157, research and development project: Name: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii

Investor: Czech Science Foundation

• MSM0021622430, plan (intention): Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies